Evotec (EVTCY) Upgraded to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Evotec (OTCMKTS:EVTCY) from a sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Several other analysts also recently commented on EVTCY. ValuEngine downgraded shares of Evotec from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Deutsche Bank downgraded shares of Evotec from a buy rating to a hold rating in a research report on Wednesday, April 10th.

Shares of Evotec stock opened at $52.04 on Tuesday. Evotec has a 12-month low of $29.48 and a 12-month high of $57.57. The firm has a market capitalization of $3.93 billion, a PE ratio of 67.85 and a beta of 1.17. The company has a quick ratio of 1.13, a current ratio of 1.16 and a debt-to-equity ratio of 0.13.

About Evotec

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.

See Also: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Evotec (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.